$MRKR News

Marker Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics Q4 EPS $(0.09) Beats $(0.47) Estimate, Sales $1.103M Beat $723.000K Estimate

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

12 Health Care Stocks Moving In Monday's After-Market Session

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Highlights Nature Medicine Publication On Multi-Antigen T Cells In Pancreatic Cancer

Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely

HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics To Present Data From Phase 1 APOLLO Study Investigating MT-601 In Patients With Relapsed B Cell Lymphomas At ASH 2025

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics Announces First Patient Treated In OTS Program, With Encouraging Preliminary Safety Data